208 related articles for article (PubMed ID: 15599383)
1. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ
Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
3. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
Wang L; Chen H; Liu F; Madigan MC; Power CA; Hao J; Patterson KI; Pourgholami MH; O'Brien PM; Perkins AC; Li Y
Cancer Lett; 2011 Jan; 300(2):122-33. PubMed ID: 21075513
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterisation of [
Hull A; Hsieh W; Tieu W; Bartholomeusz D; Li Y; Bezak E
EJNMMI Radiopharm Chem; 2023 Aug; 8(1):18. PubMed ID: 37578571
[TBL] [Abstract][Full Text] [Related]
6. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
7. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
8. The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Escarbe S; Ruszkiewicz A; Bezak E
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33379259
[TBL] [Abstract][Full Text] [Related]
9. Targeted alpha therapy approach to the management of pancreatic cancer.
Allen BJ; Rizvi SM; Qu CF; Smith RC
Cancers (Basel); 2011 Apr; 3(2):1821-43. PubMed ID: 24212784
[TBL] [Abstract][Full Text] [Related]
10. Development of [
Hull A; Hsieh W; Borysenko A; Tieu W; Bartholomeusz D; Bezak E
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):22. PubMed ID: 37679594
[TBL] [Abstract][Full Text] [Related]
11. Expression of KL-6/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis.
Xu H; Inagaki Y; Seyama Y; Du G; Wang F; Kokudo N; Tang W
Oncol Rep; 2011 Aug; 26(2):371-6. PubMed ID: 21617869
[TBL] [Abstract][Full Text] [Related]
12. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
13. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment.
Zou Q; Zhang CJ; Yan YZ; Min ZJ; Li CS
J Cell Biochem; 2019 Nov; 120(11):18650-18658. PubMed ID: 31338877
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.
Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA
Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822
[TBL] [Abstract][Full Text] [Related]
15. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models.
Park JY; Hiroshima Y; Lee JY; Maawy AA; Hoffman RM; Bouvet M
PLoS One; 2015; 10(3):e0122100. PubMed ID: 25815753
[TBL] [Abstract][Full Text] [Related]
16. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
Qu CF; Song EY; Li Y; Rizvi SM; Raja C; Smith R; Morgenstern A; Apostolidis C; Allen BJ
Clin Exp Metastasis; 2005; 22(7):575-86. PubMed ID: 16475028
[TBL] [Abstract][Full Text] [Related]
18. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer.
Xu HL; Zhao X; Zhang KM; Tang W; Kokudo N
World J Gastroenterol; 2014 Sep; 20(34):12171-81. PubMed ID: 25232251
[TBL] [Abstract][Full Text] [Related]
20. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
Shimizu M; Imai M
Biol Pharm Bull; 2008 Dec; 31(12):2288-93. PubMed ID: 19043215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]